Report Overview

2023

Base Year

2018-2023

Historical Year

2024-2032

Forecast Year

North America Granulomatosis with Polyangiitis Treatment Market Analysis

Granulomatosis with polyangiitis (GPA) is a rare disorder that causes inflammation of the blood vessels in the sinuses, nose, throat, kidneys, and lungs. The condition belongs to a group of blood vessel disorders called vasculitis. Immunosuppressive agents (such as cyclophosphamide, glucocorticoids, rituximab, and azathioprine) are prescribed in different combinations for treatment. The condition can be fatal if treatment is not given to the patient on time. Increased awareness and education initiatives are improving disease recognition and management, which impacts the treatment market for granulomatosis with polyangiitis significantly. Further, increased government initiatives and funding for rare disease research and the rising advancements in personalized therapeutic approaches are expected to propel the North America granulomatosis with polyangiitis treatment market growth.

 

The market is also impacted by the entry of biosimilars that are likely to enhance access to biologic therapies for a larger patient population. For instance, in July 2023, an Indian multinational pharmaceutical company Dr. Reddy's Laboratories Ltd., announced that the biologics license application (BLA) for its proposed rituximab biosimilar (DRL_RI) was accepted for a substantive review by the United States Food and Drug Administration (FDA). DRL_RI is being clinically developed as a biosimilar candidate of Roche’s Rituxan/MabThera (rituximab), which is approved for various indications including granulomatosis with polyangiitis. The rising introduction of high-quality biosimilars is poised to foster innovation and improvement in treatment options, which will ultimately impact the market value in coming years.

 

One of the major North America granulomatosis with polyangiitis treatment market trends is the increased clinical trial activity and research collaborations focused on GPA. In November 2023, a Phase 3 clinical trial of Tavneos (approved to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) revealed that patients who received Tavneos in combination with rituximab showed higher rates of sustained remission compared to similar patient group who received prednisone. The study was published in the journal Annals of the Rheumatic Diseases and funded by the original developer ChemoCentryx which is now acquired by Amgen Inc. Thus, the growth in the clinical studies is projected to expand the understanding of this rare condition and improve patient outcomes, which will bolster the market growth.

 

North America Granulomatosis with Polyangiitis Treatment Market Report Snapshots

North America Granulomatosis with Polyangiitis Treatment Market Size

North America Granulomatosis with Polyangiitis Treatment Market Analysis

North America Granulomatosis with Polyangiitis Treatment Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The North America granulomatosis with polyangiitis treatment market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 4.90% during the forecast period of 2025-2034. 

The increasing healthcare expenditure and the rising advancements in personalized medicine are fuelling the demand for the market.

One of the significant trends in the market is the increased entry of high-quality biosimilars indicated for granulomatosis with polyangiitis. In July 2023, Dr. Reddy's Laboratories Ltd., announced that the biologics license application (BLA) for its proposed rituximab biosimilar (DRL_RI) was accepted for a substantive review by the FDA.

Based on the drug class, the market is segmented into steroids and immunosuppressant.

By route of administration, the market is divided into oral and intravenous.

Distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies.

The market segmentation by countries includes the United States and Canada.   

The key players in the market are Roche Holding AG, GlaxoSmithKline plc (GSK), Pfizer Inc., Sanofi, Bristol Myers Squibb, Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, and AstraZeneca plc.

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124